Neuropsychiatric Deviations From Normative Profiles: An MRI-Derived Marker for Early Alzheimer's Disease Detection

arXiv cs.CV / 4/2/2026

💬 OpinionSignals & Early TrendsIdeas & Deep AnalysisModels & Research

Key Points

  • The study proposes a deep learning normative modeling framework that uses structural MRI to quantify how neuropsychiatric symptoms deviate from what is typical for healthy aging.
  • A 3D CNN was trained on cognitively stable ADNI participants to predict Neuropsychiatric Inventory Questionnaire (NPIQ) scores from brain anatomy, with the “Divergence from NPIQ” (DNPI) defined by prediction–observation mismatch.
  • Higher DNPI scores were linked to subsequent Alzheimer’s disease conversion, with an adjusted odds ratio of 2.5 (p < 0.01), suggesting the biomarker can capture early, pre-cognitive disease signals.
  • The DNPI-based prediction showed performance comparable to cerebrospinal fluid AB42 biomarkers (AUC 0.74 vs 0.75), indicating potential for scalable, non-invasive screening.
  • The authors position the method as a way to distinguish aging-related neuropsychiatric patterns from early AD-related changes using MRI plus symptom data.

Abstract

Neuropsychiatric symptoms (NPS) such as depression and apathy are common in Alzheimer's disease (AD) and often precede cognitive decline. NPS assessments hold promise as early detection markers due to their correlation with disease progression and their non-invasive nature. Yet current tools cannot distinguish whether NPS are part of aging or early signs of AD, limiting their utility. We present a deep learning-based normative modelling framework to identify atypical NPS burden from structural MRI. A 3D convolutional neural network was trained on cognitively stable participants from the Alzheimer's Disease Neuroimaging Initiative, learning the mapping between brain anatomy and Neuropsychiatric Inventory Questionnaire (NPIQ) scores. Deviations between predicted and observed scores defined the Divergence from NPIQ scores (DNPI). Higher DNPI was associated with future AD conversion (adjusted OR=2.5; p < 0.01) and achieved predictive accuracy comparable to cerebrospinal fluid AB42 (AUC=0.74 vs 0.75). Our approach supports scalable, non-invasive strategies for early AD detection.